1/3 Check out this editorial with Marat Fudim, MD MHS in EJHF on GDMT & polypharmacy in HFpEF (doi.org/10.1002/ejhf.3…)

Original paper: post hoc analysis of PARAGON-HF (doi.org/10.1002/ejhf.3…)

EJHF Editor-in-Chief European Society of Cardiology Journals

🚨Stunning!🚨

REVERSAL in the decline of heart failure ☠️ in the US 1999-2021

1999-2005 ⬇️ ☠️
2005-2012 ⬇️ ☠️
2012-2019 ⬆️ ☠️
2019-2021 ⬆️⬆️☠️

Age-adjusted HF related ☠️ rates higher in 2021 vs 1999!

WT😱🆘

jamanetwork.com/journals/jamac…

JAMA Cardiology Marat Fudim, MD MHS

SGLT2is increase risk of genital mycotic infection but not #UTI . Withdrawal of #SGLT2i led to adverse outcomes in #heartfailure . SGLT2i should be continued along with treatment for mild-moderate UTI/GMI. bit.ly/3U4K3cX

(2/2) #JACC Mark Kittipibul MD Robert Mentz, MD

Moving toward a comprehensive geriatric assessment and away from chronological age when envisioning TAVI in older adults: a must-read review in JACC: Advances jacc.org/doi/10.1016/j.… JACC Journals

📌Physician perceptions, attitudes, & strategies towards implementing #GDMT 💊 in #HeartFailure with reduced ejection fraction. A survey of the #HF A of the European Society of Cardiology

#HF rEF #HF #CardioEd

🔴 Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure JACC Journals

jacc.org/doi/10.1016/j.…
#medical #MedEd #cardiology #CardioTwitter #CVD #CardioEd #medtwitter #CardioEd

See the pooled results of PIONEER-HF and PARAGLIDE-HF trial assessing safety and efficacy of sacubitril/valsartan following a worsening HF event across the spectrum of EF. bit.ly/3x8Sc8w

#JACC #HeartFailure #LVEF Robert Mentz, MD Shelley Zieroth Kavita Sharma scottdavidsolomon

🚨The 2024 ACC Expert Consensus Decision Pathway for HFrEF just landed.

This is truly a 'living document', updated with new information for clinicians and patients.

Thanks to the Writing Committee and @ACCintouch for their commitment to this work.

jacc.org/doi/10.1016/j.…

Having benefited from excellent mentors over the course of her career, a physician concludes that a true mentor is someone who has more imagination about you than you have about yourself. Read the full Perspective: nej.md/3SDFcPf

President Dwight Eisenhower's heart attack started as a national shock. It soon became a time to learn, with help from American Heart Association co-founder Dr. Paul Dudley White.
spr.ly/6013nuAYJ

#PresidentsDay #HeartMonth #AHABoldHearts

Shifting paragidms: from an “engine out of fuel” to “energy resilience” #HFpEF #metabolism

We are deeply saddened by news of Dr. Alain Cribier’s passing. “The field of cardiology is forever changed because of his vision, leadership & persistence,' said #ACCPresident B. Hadley Wilson MD. More on his life and impact here: bit.ly/3uFY48j #TAVR

US cohort of 63,759 patients with new #HFrEF

Triple #GDMT used in only 6.2% of patients at 12 months!!!

🆘🆘🆘🆘

😱 Lack of urgency
😱 Go slow
😱 Drawn out sequencing
😱 Therapeutic inertia

Is a highly ☠️ combination

Please start quadruple GDMT now

doi.org/10.1161/circul…

This beautiful review led by Iris Beldhuis Kevin Damman in Circulation describes

📌the paradox of greater risk but under treatment when #HF is accompanied by #CKD

📌the #evidence base to guide #GDMT use across #EGFR

ahajournals.org/doi/pdf/10.116…

Families never forget the #EndOfLife #conversations we have & the #care we provide their loved one

A dear patient’s son dove into this during his eulogy at her funeral🥹

What we say, how we say it, what we do in those final wks matter deeply to families

nejm.org/doi/full/10.10…

When patients with acute heart failure can tolerate higher doses of guideline-directed medical therapy, results suggest that all efforts should be made to rapidly uptitrate to optimal doses of the 3 and (likely) 4 pillars of HF medications. ja.ma/3RGvX0g

Another excellent paper by Josephine Harrington, MD and team in Journal of Cardiac Failure 🔥🔥🔥. Check it out!!
Vishal Rao Robert Mentz, MD

SGLT2i post MI trials CVCT - CardioVascular Clinical Trialists. Is the placebo of 2023 that much better than the placebo of the ‘90s? Is there still sufficient residual risk to modify? Key insights by Muthu Vaduganathan from a (cautious) comparison of EMPACT-MI and DAPA-MI #CVCT2023

Day 3 at #CVCT2023 . Should patients be treated with #SGLT2i post MI? Fantastic deep dive in the latest evidence on #SGLT2i therapy post MI at CVCT - CardioVascular Clinical Trialists

BiykemBozkurt Darren McGuire Javed Butler Muthu Vaduganathan scottdavidsolomon Faiez ZANNAD